Journal
ONCOTARGET
Volume 6, Issue 41, Pages 43267-43280Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6530
Keywords
IL-27; IDO; PD-L1; STAT; Immunology and Microbiology Section; Immune response; Immunity
Categories
Funding
- AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG5509, IG13018, IG13518]
- Italian Ministry of Health
- Compagnia di San Paolo
- FIRC (Fondazione Italiana per la Ricerca sul Cancro) [16497]
Ask authors/readers for more resources
IL-27 is a member of the IL-12 family that is produced by macrophages and dendritic cells. IL-27 inhibits the growth and invasiveness of different cancers and therefore represents a potential anti-tumor agent. By contrast, it may exert immune-regulatory properties in different biological systems. We reported that IL-27 induces the expression of the IL-18 inhibitor IL-18BP, in human Epithelial Ovarian Cancer (EOC) cells, thus potentially limiting the immune response. Here, we tested whether IL-27 may modulate other immune-regulatory molecules involved in EOC progression, including Indoleamine 2,3-dioxygenase (IDO) and Programmed Death-Ligand (PDL) 1. IDO and PD-L1 were not constitutively expressed by EOC cells in vitro, but IL-27 increased their expression through STAT1 and STAT3 tyrosine phosphorylation. Differently, cells isolated from EOC ascites showed constitutive activation of STAT1 and STAT3 and IDO expression. These findings, together with the expression of IL-27 in scattered leukocytes in EOC ascites and tissues, suggest a potential role of IL-27 in immune-regulatory networks of EOC. In addition, IL-27 induced IDO or PD-L1 expression in monocytes and in human PC3 prostate and A549 lung cancer cells. A current paradigm in tumor immunology is that tumor cells may escape from immune control due to adaptive resistance mediated by T cell-secreted IFN-gamma, which induces PD-L1 and IDO expression in tumor cells. Our present data indicate that also IL-27 has similar activities and suggest that the therapeutic use of IL-27 as anti-cancer agent may have dual effects, in some tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available